쿼인 파머슈티컬스(ADR)(QNRX)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $7.06 (+0.71%), 시가총액 $10.12M, 52주 범위 $5.17 ~ $22.30.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology.
쿼인 파머슈티컬스(ADR)의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
쿼인 파머슈티컬스(ADR)의 현재 주가는 $7.06 (+0.71%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
쿼인 파머슈티컬스(ADR)의 시가총액은 약 $10.12M입니다.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.